DE102009052972A1 - Verfahren zur Verhinderung der Kristallisation von Arzneistoffen in einem Polymerfilm - Google Patents

Verfahren zur Verhinderung der Kristallisation von Arzneistoffen in einem Polymerfilm Download PDF

Info

Publication number
DE102009052972A1
DE102009052972A1 DE102009052972A DE102009052972A DE102009052972A1 DE 102009052972 A1 DE102009052972 A1 DE 102009052972A1 DE 102009052972 A DE102009052972 A DE 102009052972A DE 102009052972 A DE102009052972 A DE 102009052972A DE 102009052972 A1 DE102009052972 A1 DE 102009052972A1
Authority
DE
Germany
Prior art keywords
drug
matrix
polymer
temperature
crystallization
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
DE102009052972A
Other languages
German (de)
English (en)
Inventor
Dr. Leonhard Johannes Josef
Dr. Müller Walter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LTS Lohmann Therapie Systeme AG
Original Assignee
LTS Lohmann Therapie Systeme AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43877347&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE102009052972(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by LTS Lohmann Therapie Systeme AG filed Critical LTS Lohmann Therapie Systeme AG
Priority to DE102009052972A priority Critical patent/DE102009052972A1/de
Priority to BR112012011297A priority patent/BR112012011297B8/pt
Priority to JP2012538214A priority patent/JP5837883B2/ja
Priority to EP10773582.1A priority patent/EP2498762B1/fr
Priority to CN201610942520.3A priority patent/CN106619578B/zh
Priority to US13/504,970 priority patent/US8932665B2/en
Priority to EA201270618A priority patent/EA025301B1/ru
Priority to PCT/EP2010/006535 priority patent/WO2011057714A2/fr
Priority to ES10773582.1T priority patent/ES2594765T3/es
Priority to PL10773582T priority patent/PL2498762T3/pl
Priority to MX2012005511A priority patent/MX2012005511A/es
Priority to CA2780787A priority patent/CA2780787C/fr
Priority to AU2010318328A priority patent/AU2010318328B2/en
Priority to KR1020127014898A priority patent/KR101685736B1/ko
Priority to CN2010800514221A priority patent/CN102770128A/zh
Priority to TW099138797A priority patent/TWI489998B/zh
Priority to ARP100104207A priority patent/AR079028A1/es
Publication of DE102009052972A1 publication Critical patent/DE102009052972A1/de
Priority to IL219674A priority patent/IL219674B/en
Priority to US14/056,025 priority patent/US9408809B2/en
Priority to JP2015179315A priority patent/JP6161668B2/ja
Priority to JP2017083469A priority patent/JP6374566B2/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Application Of Or Painting With Fluid Materials (AREA)
DE102009052972A 2009-11-12 2009-11-12 Verfahren zur Verhinderung der Kristallisation von Arzneistoffen in einem Polymerfilm Pending DE102009052972A1 (de)

Priority Applications (21)

Application Number Priority Date Filing Date Title
DE102009052972A DE102009052972A1 (de) 2009-11-12 2009-11-12 Verfahren zur Verhinderung der Kristallisation von Arzneistoffen in einem Polymerfilm
CN2010800514221A CN102770128A (zh) 2009-11-12 2010-10-26 防止药物在聚合物薄膜中结晶的方法
MX2012005511A MX2012005511A (es) 2009-11-12 2010-10-26 Metodo para prevenir la cristalizacion de sustancias farmaceuticas en una pelicula de polimero.
AU2010318328A AU2010318328B2 (en) 2009-11-12 2010-10-26 Method for preventing the crystallisation of pharmaceuticals in a polymer film
EP10773582.1A EP2498762B1 (fr) 2009-11-12 2010-10-26 Procédé pour empêcher la cristallisation de substances pharmaceutiques dans un film polymère
CN201610942520.3A CN106619578B (zh) 2009-11-12 2010-10-26 防止药物在聚合物薄膜中结晶的方法
US13/504,970 US8932665B2 (en) 2009-11-12 2010-10-26 Method for preventing the crystallisation of pharmaceuticals in a polymer film
EA201270618A EA025301B1 (ru) 2009-11-12 2010-10-26 Способ предотвращения кристаллизации лекарственных веществ в полимерной пленке
PCT/EP2010/006535 WO2011057714A2 (fr) 2009-11-12 2010-10-26 Procédé pour empêcher la cristallisation de substances pharmaceutiques dans un film polymère
ES10773582.1T ES2594765T3 (es) 2009-11-12 2010-10-26 Procedimiento para la prevención de la cristalización de medicamentos en una película de polímero
PL10773582T PL2498762T3 (pl) 2009-11-12 2010-10-26 Sposób zapobiegania krystalizacji substancji leczniczych w filmie polimerowym
BR112012011297A BR112012011297B8 (pt) 2009-11-12 2010-10-26 processo para impedir a cristalização do medicamento rotigotina em um filme polimérico
CA2780787A CA2780787C (fr) 2009-11-12 2010-10-26 Procede pour empecher la cristallisation de substances pharmaceutiques dans un film polymere
JP2012538214A JP5837883B2 (ja) 2009-11-12 2010-10-26 ポリマーフィルム中の医薬の結晶化を防止する方法
KR1020127014898A KR101685736B1 (ko) 2009-11-12 2010-10-26 중합체 필름 내 약제의 결정화를 방지하는 방법
TW099138797A TWI489998B (zh) 2009-11-12 2010-11-11 防止聚合物薄膜中活性藥劑成分結晶化的方法
ARP100104207A AR079028A1 (es) 2009-11-12 2010-11-12 Metodo para evitar la cristalizacion de productos farmaceuticos en una pelicula polimerica
IL219674A IL219674B (en) 2009-11-12 2012-05-08 Methods to prevent crystallization of pharmaceutical substances with polymer coating
US14/056,025 US9408809B2 (en) 2009-11-12 2013-10-17 Method for preventing the crystallization of pharmaceuticals in a polymer film
JP2015179315A JP6161668B2 (ja) 2009-11-12 2015-09-11 ポリマーフィルム中の医薬の結晶化を防止する方法
JP2017083469A JP6374566B2 (ja) 2009-11-12 2017-04-20 ポリマーフィルム中の医薬の結晶化を防止する方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102009052972A DE102009052972A1 (de) 2009-11-12 2009-11-12 Verfahren zur Verhinderung der Kristallisation von Arzneistoffen in einem Polymerfilm

Publications (1)

Publication Number Publication Date
DE102009052972A1 true DE102009052972A1 (de) 2011-09-15

Family

ID=43877347

Family Applications (1)

Application Number Title Priority Date Filing Date
DE102009052972A Pending DE102009052972A1 (de) 2009-11-12 2009-11-12 Verfahren zur Verhinderung der Kristallisation von Arzneistoffen in einem Polymerfilm

Country Status (17)

Country Link
US (2) US8932665B2 (fr)
EP (1) EP2498762B1 (fr)
JP (3) JP5837883B2 (fr)
KR (1) KR101685736B1 (fr)
CN (2) CN106619578B (fr)
AR (1) AR079028A1 (fr)
AU (1) AU2010318328B2 (fr)
BR (1) BR112012011297B8 (fr)
CA (1) CA2780787C (fr)
DE (1) DE102009052972A1 (fr)
EA (1) EA025301B1 (fr)
ES (1) ES2594765T3 (fr)
IL (1) IL219674B (fr)
MX (1) MX2012005511A (fr)
PL (1) PL2498762T3 (fr)
TW (1) TWI489998B (fr)
WO (1) WO2011057714A2 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010040020A1 (fr) 2008-10-02 2010-04-08 Salix Pharmaceuticals, Ltd. Méthodes de traitement d’une encéphalopathie hépatique
DE102011090178A1 (de) * 2011-12-30 2013-07-04 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System mit geringer Neigung zur Spontankristallisation
TW201431570A (zh) 2012-11-22 2014-08-16 Ucb Pharma Gmbh 用於經皮投服羅替戈汀（Ｒｏｔｉｇｏｔｉｎｅ）之多天式貼片
CN103919755B (zh) * 2013-01-15 2019-10-18 江苏康倍得药业股份有限公司 妥洛特罗透皮贴剂及其制备方法
CA2916183C (fr) 2013-07-03 2022-03-29 Lts Lohmann Therapie-Systeme Ag Systeme therapeutique transdermique dote d'un composant electronique
EP3145503A1 (fr) * 2014-05-20 2017-03-29 LTS Lohmann Therapie-Systeme AG Méthode de régulation de libération d'agent actif dans un système d'administration transdermique
CA2948221C (fr) 2014-05-20 2022-11-22 Lts Lohmann Therapie-Systeme Ag Systeme d'administration transdermique comprenant un mediateur d'interface
WO2015177204A1 (fr) * 2014-05-20 2015-11-26 Lts Lohmann Therapie-Systeme Ag Système d'administration transdermique contenant de la rotigotine
KR102363218B1 (ko) 2017-12-19 2022-02-14 히사미쓰 세이야꾸 가부시키가이샤 로티고틴 함유 첩부제
JP7399633B2 (ja) * 2019-06-14 2023-12-18 株式会社大石膏盛堂 経皮吸収型製剤の製造方法
DE102019117870B3 (de) * 2019-07-02 2020-11-26 Lts Lohmann Therapie-Systeme Ag Oraler Dünnfilm
PL3854388T3 (pl) 2020-01-24 2024-02-26 Luye Pharma Switzerland Ag Transdermalny system terapeutyczny z substancją czynną rotygotyną i co najmniej jednym klejem silikonowym nieodpornym na działanie amin

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4832953A (en) 1987-08-13 1989-05-23 Alza Corporation Method for preventing the formation of a crystalline hydrate in a dispersion of a liquid in a monaqueous matrix
US5662928A (en) 1995-04-21 1997-09-02 Ciba-Geigy Corporation Method for the prevention or removal of crystalline scopolamine in a non-aqueous matrix of a transdermal system

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH066534B2 (ja) 1986-10-09 1994-01-26 積水化学工業株式会社 経皮吸収貼付剤
ATE207348T1 (de) 1995-12-01 2001-11-15 Alza Corp Verbessertes verfahren zur verhinderung der kristallbildung in einer dispersion eines flüssigen stoffes in einer matrix
CA2302411C (fr) * 1997-09-02 2007-01-30 Novartis Ag Procede ameliore destine a empecher la formation de cristaux dans un dispositif d'administration transdermique de scopolamine
DE19954936A1 (de) 1999-11-16 2001-05-17 Bayer Ag Verfahren zur Herstellung von Benzofuranonoximen
AU1613101A (en) 1999-11-23 2001-06-04 Aderis Pharmaceuticals, Inc. Improved process for preparing nitrogen-substituted aminotetralins
US20020119187A1 (en) 2000-09-29 2002-08-29 Cantor Adam S. Composition for the transdermal delivery of fentanyl
DK1256340T3 (da) 2001-05-08 2003-12-01 Sanol Arznei Schwarz Gmbh Forbedret transdermalt, terapeutisk system til behandlingen af Parkinsons sygdom
DE10234673B4 (de) * 2002-07-30 2007-08-16 Schwarz Pharma Ag Heißschmelz-TTS zur Verabreichung von Rotigotin und Verfahren zu seiner Herstellung sowie Verwendung von Rotigotin bei der Herstellung eines TTS im Heißschmelzverfahren
DE10261696A1 (de) * 2002-12-30 2004-07-15 Schwarz Pharma Ag Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base
JP4641394B2 (ja) 2004-08-06 2011-03-02 リンテック株式会社 経皮吸収型製剤の製造方法
US8524695B2 (en) * 2006-12-14 2013-09-03 Knopp Neurosciences, Inc. Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
US20090197824A1 (en) * 2008-01-31 2009-08-06 Methylation Sciences International Srl Extended Release Pharmaceutical Formulations of S-Adenosylmethionine
US20080226698A1 (en) 2007-03-16 2008-09-18 Mylan Technologies, Inc. Amorphous drug transdermal systems, manufacturing methods, and stabilization
WO2008146284A2 (fr) 2007-05-30 2008-12-04 Chemagis Ltd. Base de rotigotine cristalline et son procédé de préparation
WO2009053697A1 (fr) 2007-10-26 2009-04-30 Pliva Hrvatska D.O.O. Formes polymorphes du chlorhydrate de (s)-rotigotine
WO2009063171A1 (fr) 2007-11-16 2009-05-22 Pliva Hrvatska D.O.O. Nouveaux sels de rotigotine
CN101970422B (zh) 2007-11-28 2014-10-22 Ucb制药有限公司 罗替高汀的多晶型物
WO2009122429A2 (fr) * 2008-02-04 2009-10-08 Matrix Laboratories Limited Oxybutynine cristalline et son procédé de préparation
IT1392387B1 (it) 2008-09-26 2012-03-02 Solmag S P A Ora Fidia Farmaceutici S P A Processo per la preparazione di rotigotina
US20100086582A1 (en) 2008-10-06 2010-04-08 Mylan Technologies, Inc. Amorphous rotigotine transdermal system
WO2010073124A2 (fr) 2008-12-26 2010-07-01 Actavis Group Ptc Ehf Procédé de préparation de rotigotine très pure ou d'un sel pharmaceutiquement acceptable de celle-ci
EP2201941A1 (fr) 2008-12-29 2010-06-30 UCB Pharma GmbH Technologie de fabrication de pavé

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4832953A (en) 1987-08-13 1989-05-23 Alza Corporation Method for preventing the formation of a crystalline hydrate in a dispersion of a liquid in a monaqueous matrix
US5662928A (en) 1995-04-21 1997-09-02 Ciba-Geigy Corporation Method for the prevention or removal of crystalline scopolamine in a non-aqueous matrix of a transdermal system

Also Published As

Publication number Publication date
BR112012011297B1 (pt) 2020-12-15
US8932665B2 (en) 2015-01-13
EP2498762A2 (fr) 2012-09-19
PL2498762T3 (pl) 2017-02-28
CA2780787A1 (fr) 2011-05-19
CN106619578B (zh) 2021-10-01
WO2011057714A2 (fr) 2011-05-19
JP2013510805A (ja) 2013-03-28
KR101685736B1 (ko) 2016-12-12
ES2594765T3 (es) 2016-12-22
EP2498762B1 (fr) 2016-09-07
IL219674B (en) 2018-10-31
KR20120115258A (ko) 2012-10-17
TW201124156A (en) 2011-07-16
AU2010318328A1 (en) 2012-05-31
US20140046279A1 (en) 2014-02-13
EA025301B1 (ru) 2016-12-30
US20120213912A1 (en) 2012-08-23
BR112012011297A2 (pt) 2016-04-12
IL219674A0 (en) 2012-07-31
MX2012005511A (es) 2012-06-14
WO2011057714A3 (fr) 2011-07-07
CA2780787C (fr) 2017-11-07
JP2017149758A (ja) 2017-08-31
AU2010318328B2 (en) 2015-01-22
JP2016028078A (ja) 2016-02-25
AR079028A1 (es) 2011-12-21
JP5837883B2 (ja) 2015-12-24
JP6374566B2 (ja) 2018-08-15
TWI489998B (zh) 2015-07-01
BR112012011297B8 (pt) 2021-05-25
CN102770128A (zh) 2012-11-07
JP6161668B2 (ja) 2017-07-12
US9408809B2 (en) 2016-08-09
CN106619578A (zh) 2017-05-10
EA201270618A1 (ru) 2013-01-30

Similar Documents

Publication Publication Date Title
EP2498762B1 (fr) Procédé pour empêcher la cristallisation de substances pharmaceutiques dans un film polymère
EP1490052B1 (fr) Dispositif pour l'administration transdermique de base de rotigotine
DE602004007888T2 (de) Transdermal granisetron
DE602004010248T2 (de) Externes pflaster mit östrogen und/oder gestagen
DE10012908B4 (de) Stabilisierte übersättigte transdermale therapeutische Matrixsysteme und Verfahren zu ihrer Herstellung
EP2797588B1 (fr) Système thérapeutique transdermique présentant une tendance réduite à la cristallisation spontanée
EP2111857A1 (fr) Système thérapeutique transdermique destiné à l'application de fentanyle ou d'une matière analogue
DE10212864A1 (de) Mischsystem zur Löslichkeitsvermittlung von pharmazeutischen Wirkstoffen in Polymermatrizes
EP1894563B2 (fr) Pavé contenant du fentanyl
DE102012013421A1 (de) Transdermales therapeutisches System (TTS) mit Rotigotin
EP0781134A1 (fr) Emplatre a la scopolamine
EP2714018B1 (fr) Systeme transdermique comprenant de la buprenorphine ainsi qu'un alpha hydroxy acide
EP3713549B1 (fr) Systeme therapeutique transdermique a base de plastifiant-polymere-matrices
DE102012013439A1 (de) Transdermales therapeutisches System umfassend Rotigotin und Kristallisationsinhibitor
DE102017124627A1 (de) Transdermales Darreichungssystem enthaltend einen Dopaminagonisten
EP2614820A1 (fr) Système thérapeutique transdermique doté d'un inhibiteur de la cholinestérase
DE102010040299A1 (de) Transdermale therapeutische Systeme mit kristallisationsinhibierender Schutzfolie (Release Liner)
DE4229230C2 (de) Transdermales therapeutisches System mit Pentetrazol als Wirkstoff
DE102017115701B4 (de) Fampridin-TTS
EP3725300A1 (fr) Système d'administration transdermique comprenant des inhibiteurs de l'aromatase
DE102018118507A1 (de) Transdermales therapeutisches System zur Abgabe von Scopolamin ohne Membran
WO2008064815A2 (fr) Préparation pour l'administration transdermique de galanthamine

Legal Events

Date Code Title Description
R082 Change of representative

Representative=s name: PLATE SCHWEITZER ZOUNEK PATENTANWAELTE, DE

R016 Response to examination communication
R016 Response to examination communication